Back to ranking
#1USNASDAQMid-cap

EXEL

Exelixis

$59.13USD

Data as of 2026-09-05

Fair value$29.16
Target$114.20
Loss chance45%Neutral

Company attributes

SizeLarge cap
SectorHealth Care
Dividend
TypeCommon stock

Price

Interactive 5-year price history chart for EXEL. Latest close $59.13.

Loading price history…

Pillar breakdown

0–100 percentile rank against the current universe (sector-relative for Quality / Value / Growth / Profitability)

Health Care median (n=163)
  • Quality
    Profit margins & asset efficiency
    94
    Exceptional
    Health Care median (n=163) 51
  • Value
    Price vs fundamentals
    62
    Strong
    Health Care median (n=163) 51
  • Growth
    Revenue & earnings trajectory
    87
    Exceptional
    Health Care median (n=163) 50
  • Momentum
    Recent price strength
    79
    Exceptional
    Health Care median (n=163) 62
  • Health
    Balance sheet & solvency
    79
    Exceptional
    Health Care median (n=163) 56
  • Profitability
    ROE, ROA, ROIC
    95
    Exceptional
    Health Care median (n=163) 49
  • Technical
    Trend & volatility signals
    62
    Strong
    Health Care median (n=163) 62
  • Risk
    Volatility & drawdown profile
    74
    Exceptional
    Health Care median (n=163) 47
025405570100
Exceptional (70+)Strong (55–70)Average (40–55)Weak (25–40)Poor (<25)

Pillars not shown: Sentiment, ML (Phase 5+).

Fair price check

6 different valuation methods each estimate what EXEL should be worth, then we compare to today's price.

Heavily overvalued
Models suggest EXEL is far above estimated fair value
Today's price
$59.13
Median fair price
$29.16
-51% vs today's price
Of 6 methods:2 say cheap4 say pricey
  • EV/EBITDAUndervalued
    thinks it's a bargainestimates $114.20, about 93% above today
  • P/E multiplesUndervalued
    thinks it's a bargainestimates $95.39, about 61% above today
  • P/B multiplesOvervalued
    thinks it's expensiveestimates $40.39, about 32% below today
  • DCF (2-stage)Overvalued
    thinks it's expensiveestimates $17.93, about 70% below today
  • Graham (defensive)Overvalued
    thinks it's expensiveestimates $16.72, about 72% below today
  • Residual IncomeOvervalued
    thinks it's expensiveestimates $12.21, about 79% below today

How to read this: “Cheap” = method's fair price is at least 20% above today. “Fair” = within ±10–20%. “Pricey” = at least 10% below today. Outliers (values more than 5× or less than 0.2× today's price) are excluded.

Fair price ensemble

Median fair
$29.16
Margin of safety(vs fair value)
< −99%
Max (ex-outliers)
$114.20
Tangible BVPS
$7.18

Median of all applicable methods (current price $59.13). Per-method estimates + each method’s cheap/fair/pricey read are in the Fair price check above. Outliers above 5× or below 0.2× current price are excluded from the max but kept in the median. See methodology for the 6-method ensemble + 7 defenses.

Defense layer. Flags mark elevated risk, never confirmed fraud. This model cannot catch every manipulation and decays after publication — weigh it against its stated error rates.

Supporting dataRaw fundamentals & data-quality provenance behind the scores above

Raw fundamentals (SEC EDGAR)

MetricValue
Market cap$14.65B
Revenue (TTM)$2.44B
Net income (TTM)$860.62M
Operating cash flow (TTM)$1.18B
CapEx (TTM)$10.96M
Free cash flow (TTM)CFO − CapEx$1.17B
Total assets$2.49B
Total liabilities$650.47M
Stockholders' equity$1.84B
Cash & equivalents$281.45M
Shares outstanding247.78M
EPS (basic)$3.47
EPS (diluted)$3.47
P/E ratio (TTM)17.02

TTM = trailing twelve months. Balance sheet items are point-in-time (latest filing).

Data quality

Latest filed date
2026-08-05
Latest period end
2026-07-27
Filing lag
31 days
Missing metrics
6(gross_profit, interest_expense, income_before_tax, dividends_paid, accounts_receivable, intangibles_net)

Composite is the 8-pillar weighted score over quality, value, growth, momentum, health, profitability, technical, and risk. Sentiment + ML pillars are reserved for a later phase; until then their weight redistributes pro-rata. Fair price is the median of 6 valuation methods (Graham, P/E / P/B / EV-EBITDA multiples, RIM, DCF) with outliers above 5× current price excluded from the max. Risk-overlay flags annotate only — they suppress the entered-top-5 badge but do not modify the composite.